By Spondylitis Association of America
A phase 3 clinical trial is now recruiting non-radiographic axial Spondyloarthritis (nr-axSpA) patients over the age of 18 to participate in a study of an investigational biologic medication, secukinumab, given by injection.
By The George Washington University
In an increasingly connected and busy world, workers in many fields complain about working themselves “to death” in an attempt to “have it all.” While the phrase is often meant as hyperbole, studies continue to find that heavy workloads, family stressors, decreased free time and unhealthy personal habits really are dangerous for our health.
On November 4, 2017 the Spondylitis Association of America hosted a free Spondylitis Educational Seminar in San Diego, CA. Our speakers for the day were Rheumatologist John Reveille, MD and Physical Therapist Angelo Papachristos, MBA, BSc (PT).
As of December 1, 2017, the FDA has officially approved Taltz injection 80 mg/mL for treatment of patients with active psoriatic arthritis.
New evidence, presented by Alexander Egeberg, MD, PhD, University of Copenhagen, and colleagues in the Journal of the American Academy of Dermatology suggests that patients with psoriasis or any related form of the condition, such as psoriatic arthritis, have a higher risk of experiencing a cardiovascular disease event (CVD) compared to non-afflicted individuals.
Visit our careers page for available positions
16360 Roscoe Blvd. Ste. 100Van Nuys, CA 91406
(800) 777-8189 U.S. only
or (818) 892-1616*Please note: This is not a Crisis Hotline. If you are in a life-threatening crisis, please dial 911 for immediate help in the US. Please follow this link for crisis intervention resources.